Talk to Tecan @ SLAS2014
14 January 2014 | By kdm Communications
Join Tecan on booth #405 at this year’s SLAS Conference and Exhibition in San Diego, California, to discover the latest developments in automated liquid handling...
List view / Grid view
News
Statement regarding FDA inspection of Ranbaxy’s Toansa plant
14 January 2014 | By Daiichi Sankyo Co., Ltd
Ranbaxy received the form 483 with certain observations as a result of the recent US FDA inspection at its API plant at Toansa, Punjab, India...
AstraZeneca provides update at JP Morgan Healthcare Conference on progress to achieve scientific leadership and return to growth
14 January 2014 | By AstraZeneca
At the conference, Pascal Soriot will provide an update on the company’s development pipeline and outline its strategic priorities for 2014...
Merck provides update on accelerated strategic actions for growth at 32nd Annual J.P. Morgan Healthcare conference
13 January 2014 | By Merck
“We’re taking significant and decisive action to make Merck a more competitive company, better positioned to drive innovation and growth...”
Prosensa regains rights to drisapersen from GSK and retains rights to all other programmes for the treatment of Duchenne muscular dystrophy (DMD)
13 January 2014 | By GlaxoSmithKline
This transfer of rights represents the termination of the collaboration agreement between GSK and Prosensa executed in 2009....
Data demonstrates key genes respond differently to COPAXONE® (glatiramer acetate injection) versus a purported generic glatiramer acetate
13 January 2014 | By Teva Pharmaceuticals Industries Ltd
Multiple genes associated with potential therapeutic effects expressed differently: Gene expression analysis provides insight into variability...
Genzyme and Alnylam expand collaboration on rare genetic diseases
13 January 2014 | By Sanofi
Genzyme will have significant rights to Alnylam’s portfolio of clinical and pre-clinical stage drug candidates...
US FDA approves FARXIGA™ (dapagliflozin) tablets for the treatment of adult patients with type 2 diabetes
13 January 2014 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced the FDA approved FARXIGA™ (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus...
Hervé Hoppenot, President of Novartis Oncology, leaves Novartis to pursue career opportunity outside of organization
12 January 2014 | By Novartis
Novartis announced that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect...
Thomas Broeer elected as new BGMA Chair
The British Generic Manufacturers Association (BGMA) has appointed Thomas Broeer, managing director of Kent Pharmaceuticals, as its new chair for the next two years.
Biogen Idec and Sangamo BioSciences announce global collaboration to develop treatments for Hemoglobinopathies
9 January 2014 | By Biogen Idec
“Our collaboration with Sangamo is expected to help us expand our capabilities to develop treatments for people with serious, inherited hematologic conditions..."
Teva names Erez Vigodman as President and CEO
9 January 2014 | By Teva
“I would like to welcome Erez to his new position as the CEO of Teva..."
Allergan’s BOTOX® (botulinum toxin type A) receives national marketing authorisation for treatment of moderate to severe crow’s feet lines in adult patients
9 January 2014 | By Allergan
New aesthetic indication for market-leading neuromodulator which can now help improve appearance of lines around the eyes, as well as treating glabellar frown lines...
Daiichi Sankyo submits SAVAYSA(TM) (edoxaban) tablets New Drug Application to the U.S. FDA
9 January 2014 | By Daiichi Sankyo
Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism...
Daiichi Sankyo, Virtici and Celdara Medical announce collaboration to identify and progress high potential therapeutics
8 January 2014 | By Daiichi Sankyo
Virtici and Celdara Medical are affiliated, independent companies that build and develop pipelines of high potential therapeutic assets...
